Sugi Predict

Sugi Predict / Compounds / SCHEMBL458270

SCHEMBL458270

SCHEMBL458270

OCc1cc(F)ccc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.38
▸ DPP4 P27487 2/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PLEC Q15149 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CA3 P07451 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ CA5B Q9Y2D0 1/20 0.34
▸ FFAR1 O14842 1/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ NR3C1 P04150 1/20 0.34
▸ RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30227514 1.00 PKM (0.38) PKMDPP4MEN1ALDH1A1POLB
Ammonia Solution, Strong SCHEMBL28943169 0.98 PKM (0.37) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL31021710 0.84 DPP4 (0.37) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL30360615 0.83 PKM (0.36) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL485871 0.83 PKM (0.36) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL901450 0.82 PKM (0.42) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL31573752 0.82 PKM (0.42) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL30817979 0.79 CA2 (0.42) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL17980199 0.79 CA2 (0.42) PKMDPP4MEN1ALDH1A1POLB
SCHEMBL31441340 0.79 GPR84 (0.34) PKMDPP4MEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182496-A1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES HALCYON LABS PRIVATE LIMITED (IN) 2024-06-06 — — US claimed
EP-3704100-B1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES HALCYON LABS PRIVATE LTD (IN) 2023-08-30 — — EP claimed
CN-114933607-A Preparation method of 4-fluoro-2-hydroxymethyl phenylboronic acid and cliborole 山东诺明康药物研究院有限公司 2022-08-23 — — CN claimed
CN-114249756-A Synthetic method of tavabororo 广东和博制药有限公司 2022-03-29 — — CN claimed
EP-3704100-A1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES Halcyon Labs Private Limited (IN) 2020-09-09 — — EP claimed
US-20200262848-A1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES HALCYON LABS PRIVATE LIMITED (IN) 2020-08-20 — — US claimed
US-12600733-B2 KRAS inhibitors ELI LILLY AND COMPANY (US) 2026-04-14 — — US disclosed
US-20260092075-A1 KRAS INHIBITORS LILLY CO ELI (US) 2026-04-02 — — US disclosed
EP-4688784-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 — — EP disclosed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 — — EP disclosed
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
EP-4655069-A1 PYRIDAZINES AS SARM1 INHIBITORS Disarm Therapeutics, Inc. (US) 2025-12-03 — — EP disclosed
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-27 — — US disclosed
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 — — EP disclosed
WO-2004009578-A2 PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ELI LILLY AND COMPANY (US) 2004-01-29 — — WO disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 — — US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 — — US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 — — WO disclosed
US-3985889-A 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS AMERICAN HOECHST CORPORATION (US) 1976-10-12 — — US disclosed
US-3962259-A TRANQUILIZERS, ANALGETIC AGENTS AMERICAN HOECHST CORPORATION (US) 1976-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP PKM 4666/4885DPP4 53/4885MEN1 2833/4885
US-12600733-B2 KRAS inhibitors KRAS, NRAS, HRAS PKM 2956/4885DPP4 4080/4885MEN1 404/4885
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof TNNT2, TNNI3, TNNC1 PKM 3860/4885DPP4 3481/4885MEN1 3410/4885
US-20240182496-A1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES TALDO1, TFPI, SQLE PKM 1084/4885DPP4 1250/4885MEN1 3074/4885
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA PKM 485/4885DPP4 344/4885MEN1 2996/4885
US-20260092075-A1 KRAS INHIBITORS KRAS, NRAS, HRAS PKM 3184/4885DPP4 4053/4885MEN1 511/4885
US-20200262848-A1 NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES TALDO1, TFPI, SQLE PKM 1084/4885DPP4 1250/4885MEN1 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.